menu
    • menu
    [{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Vaneltix Pharma \/ Vaneltix Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Vaneltix Pharma"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0.01,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Vaneltix Pharma \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Prevail Infoworks","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VNX001","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Vaneltix Pharma \/ Prevail Infoworks","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Prevail Infoworks"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Prevail Infoworks","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VNX001","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Vaneltix Pharma \/ Prevail Infoworks","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Prevail Infoworks"}]

    Find Clinical Drug Pipeline Developments & Deals by Vaneltix Pharma

    Menu

    Vaneltix Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vaneltix Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Vaneltix Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VNX001

                            Therapeutic Area : Urology

                            Study Phase : Phase II

                            Sponsor : Prevail Infoworks

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladde...

                            Details : VNX001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystitis, Interstitial.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 01, 2024

                            Lead Product(s) : VNX001

                            Therapeutic Area : Urology

                            Highest Development Status : Phase II

                            Sponsor : Prevail Infoworks

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vaneltix Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Vaneltix Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Heparin Sodium

                            Therapeutic Area : Urology

                            Study Phase : Phase II

                            Recipient : Hyloris Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hyloris Announces Enrolment of First Patient in a 4-Arm Clinical Trial of Alenura(TM)

                            Details : Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.

                            Product Name : Alenura

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 22, 2023

                            Lead Product(s) : Lidocaine,Heparin Sodium

                            Therapeutic Area : Urology

                            Highest Development Status : Phase II

                            Recipient : Hyloris Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vaneltix Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Vaneltix Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VNX001

                            Therapeutic Area : Urology

                            Study Phase : Phase II

                            Sponsor : Prevail Infoworks

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo i...

                            Details : VNX001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystitis, Interstitial.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 21, 2023

                            Lead Product(s) : VNX001

                            Therapeutic Area : Urology

                            Highest Development Status : Phase II

                            Sponsor : Prevail Infoworks

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vaneltix Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Vaneltix Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Heparin Sodium

                            Therapeutic Area : Urology

                            Study Phase : Phase II

                            Sponsor : Hyloris Pharmaceuticals

                            Deal Size : $6.7 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in Interstitial Cystitis

                            Details : Under the terms of the agreement, Vaneltix will be responsible for the further development, manufacturing, regulatory affairs and commercialisation of AlenuraTM in collaboration with Hyloris.

                            Product Name : Alenura

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 17, 2021

                            Lead Product(s) : Lidocaine,Heparin Sodium

                            Therapeutic Area : Urology

                            Highest Development Status : Phase II

                            Sponsor : Hyloris Pharmaceuticals

                            Deal Size : $6.7 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth